Real-world study of pegylated interferon α-2a to treat mycosis fungoides/Sézary syndrome using time to next treatment as a measure of clinical benefit: an EORTC CLTG study.
Keila MitsunagaMartine BagotCaroline Ram-WolffEmmanuella GuenovaChristina von GugelbergEmmilia HodakIris Amitay-LaishEvangelia PapadavidConstanze JonakStefanie PorkertJulia ScarisbrickRona ApplewaiteMarie Beylot-BarryJan NicolayPietro QuaglinoJosé Antonio SanchesJade Cury-MartinsDavid Lora-PablosPablo OrtizPublished in: The British journal of dermatology (2024)
PEG-IFN-α-2a for MF/SS resulted in an ORR of 53.3% and a mean (SD) TTNT of 9.2 (10.6) months. Combination regimens were superior to monotherapy and doses of 180 µg PEG-IFN-α-2a weekly were related to a higher ORR.